本篇回應
Lin 認為 含有錯誤訊息
引用自 Lin 查核回應
淋巴癌在醫學上十分棘手,也分成非常多類型,其兇猛程度與致死率也可以有很大差異,接受治療後的存活從一周到十數年皆有。雖然40年來醫學有干擾素、B細胞受體抗體等藥劑發明,確實對一些種類的淋巴癌進展還是有限。也有活性度較低的淋巴癌,若不幸罹患淋巴癌,與醫師討論是非常重要的,了解選擇的後果與利弊後,請為自己做出最滿意的選擇。

資料佐證

https://www.hindawi.com/journals/crim/2012/457908/
Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula
https://www.ncbi.nlm.nih.gov/pubmed/1754669
The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival.

The natural history of low grade non-Hodgkin's lymphoma and the impact of a no initial treatment policy on survival. - PubMed

Q J Med. 1991 Aug;80(292):651-60.AbstractThe natural history of low grade lymphoma and the influence of a 'no initial treatment' policy on survival were studied retrospectively in a group of 153 patie

https://www.ncbi.nlm.nih.gov/pubmed/1754669
此查核回應尚被用於以下的可疑訊息

以上內容「Cofacts 真的假的」訊息回報機器人與查證協作社群提供,以 CC授權 姓名標示-相同方式分享 4.0 (CC BY-SA 4.0) 釋出,於後續重製或散布時,原社群顯名及每一則查證的出處連結皆必須被完整引用。